Sunita Hack Email

Senior Director Clinical Operations and Medical Affairs . BeyondSpring

Current Roles

Employees:
55
Revenue:
$5.5M
About
BeyondSpring Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. We are currently advancing the development of our lead asset Plinabulin, a novel cancer therapeutic, in a global Phase 3 trial in non-small-cell lung cancer (NSCLC) and initiating a pivotal global Phase 3 trial in prevention of docetaxel-induced neutropenia. As a tubulin depolymerizing agent, Plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment: 1. Immune enhancing effects via dendritic cell maturation 2. Tumor cell apoptosis via activation of RAS-JNK pathway 3. Vascular disruptive effects Given Plinabulin's potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications: • Immuno-oncology, with immune checkpoint inhibitors in NSCLC • CNS malignancies including glioblastoma (GBM) • KRAS positive mutant cancers
BeyondSpring Address
28 Liberty Street
New York, NY
United States

Past Companies

BeyondSpringSenior Director Clinical Operations and Medical Affairs
BeyondSpringDirector of Clinical Operations
Ludwig Cancer ResearchClinical Project Management: Non-Profit

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.